Detection of disseminated lung cancer cells in lymph nodes: Impact on staging and prognosis

Annals of Thoracic Surgery

Volumn 61, Issue 1, 1996, Pages 177-183

  Passlick, Bernward ^a   Izbicki, Jakob R ^b   Kubuschok, Boris ^b   Thetter, Olaf ^b   Pantel, Klaus ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT THERAPY; ARTICLE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HISTOLOGY; HUMAN; HUMAN TISSUE; LUNG CANCER; LYMPH NODE METASTASIS; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL;

EID: 0030020117     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/0003-4975(95)01012-2     Document Type: Article

References (22)

1. Riethmüller G, Johnson JP. Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers. Curr Opin Immunol 1992;4:647-55.
2. Pantel K, Koprowski H, Riethmüller G. Conference on cancer micrometastasis: biology, methodology, and clinical significance. Int J Oncol 1993;3:1019-22.
3. Schlimok G, Funke I, Bock B, Schweiberer B, Witte J, Riethmüller G. Epithelial tumor cells in bone marrow of patients with colorectal cancer: immunocytochemical detection, phenotypic characterization, and prognostic significance. J Clin Oncol 1990;8:831-7.
4. Schlimok G, Funke I, Pantel K, et al. Micrometastatic tumor cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance. Eur J Cancer 1991;27:1461-5.
5. Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmüller G. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients. Lancet 1992;340: 685-9.
6. Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 1991;9:1749-56.
7. Pantel K, Izbicki JR, Angstwurm M, et al. Immunocytological detection of bone marrow micrometastasis in operable non-small cell lung cancer. Cancer Res 1993;53:1027-31.
8. Passlick B, Izbicki JR, Kubuschok B, et al. Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small cell lung cancer. J Clin Oncol 1994;12:1827-32.
9. Momburg F, Moldenhauer G, Hämmerling GJ, Möller P. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res 1987;47:2883-91.
10. Latza U, Niedobitek G, Schwarting R, Nekarda H, Stein H. Ber-EP4: new monoclonal antibody which distinguishes ep-ithelia from mesothelia. J Clin Pathol 1990;43:213-9.
11. Debus E, Moll R, Franke WW, Weber K, Osborn M. Immunohistochemical distinction of human carcinomas by cytokeratin typing with monoclonal antibodies. Am J Pathol 1984;114:121-30.
12. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV. Design and analysis of clinical trials requiring prolonged observation of each patient II: analysis and examples. Br J Cancer 1977;35:1-39.
13. Cox DR. Regression models and life tables. J Stat Soc 1972;34:187-220.
14. Moldenhauer G, Momburg F, Möller P, Schwartz R, Hämmerling GJ. Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker. Br J Cancer 1987;6:714-21.
15. Chen ZL, Perez S, Holmes CE, et al. Frequency and distribution of occult micrometastases in lymph nodes of patients with non-small cell lung cancer. J Natl Cancer Inst 1993;85: 493-8.
16. Domagala W, Bedner E, Chosia M, Weber K, Osborn M. Keratin-positive reticulum cells in fine needle aspirates and touch imprints of hyperplastic lymph nodes. Acta Cytol 1991;36:241-5.
17. Mountain CF. Surgery for stage IIIa-N2 non-small cell lung cancer. Cancer 1994;73:2589-98.
18. Passlick B, Izbicki JR, Simmel S, et al. Expression of major histocompatibility class I and class II antigens and intercellular adhesion molecule-1 on operable non-small cell lung carcinomas: frequency and prognostic significance. Eur J Cancer 1994;30A:376-81.
19. Redondo M, Concha R, Oldiviela A, et al. Expression of HLA class I and class II antigens in bronchogenic carcinoma: its relationship to cellular DNA content and clinical-pathological parameters. Cancer Res 1991;51:4948-54.
20. Pantel K, Schlimok G, Braun S, et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993;85: 1419-24.
21. Pantel K, Dickmanns A, Zippelius A, et al. Establishment of micrometastatic carcinoma cell lines: a novel source of tumor cell vaccines. J Natl Cancer Inst 1995;87:1162-8.
22. Riethmüller G, Schneider-Gädicke E, Schlimok G, et al. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. Lancet 1994; 343:1177-83.